On August 22, AccuMedical’s grism® Distal Closed Intracranial Thrombectomy Stent was successfully approved for registration by the National Medical Products Administration (NMPA). Registration Certificate Number: NMPA 20253031621.
The grism® Distal Closed Intracranial Thrombectomy Stent is primarily used for the treatment of ischemic stroke. After being delivered through the arterial pathway to the site of intracranial thromboembolism, the stent self-expands to establish an immediate blood flow channel, allowing penumbral brain cells to be reperfused. The stent is then retracted to capture and remove the thrombus, restoring cerebral blood flow and perfusion, thereby reducing mortality and disability rates.
The grism® stent features a globally unique and innovative multifunctional radiopaque claw design, a closed atraumatic tip, a flower-pattern mesh structure, and advanced surface treatment technology. It can be delivered through small-size microcatheters and is available in a broader range of models and sizes. During clinical procedures, the device demonstrates excellent thrombus integration, strong clot capture capability, low risk of clot fragmentation and escape, and high precision in intraoperative positioning.
To date, AccuMedical has obtained NMPA approvals for more than 10 innovative products, including Lattice®, Lattice® NEXT, attractor®, cosine®, sine®, achieving full coverage of neurointervention scenarios for hemorrhagic stroke, ischemic stroke, and access support. The company has filed 135 patent applications, 76 of which have been granted, forming a robust and high-barrier intellectual property portfolio.
As one of the key drafting units of the national industry standard for neurovascular thrombectomy stents, AccuMedical actively participates in the standardization of medical device evaluation in China, continuously promoting improvements in industry quality. Leveraging its innovation strength and industrialization achievements, the company has been recognized as a National High-Tech Enterprise in 2023 and a National-level “Little Giant” Enterprise in 2024.